Introduction
NuraLogix is a Toronto-based digital health technology company founded in 2015 that measures physiological and psychological states from facial video using patented Transdermal Optical Imaging. Marzio Pozzuoli co-founded NuraLogix with Dr. Kang Lee and serves as chief executive officer per the company’s May 2021 MedTech Breakthrough award announcement reviewed in July 2026.
NuraLogix sits at the intersection of Affective AI and contactless monitoring — extracting blood flow signals through smartphone cameras rather than cuffs, wearables, or dedicated medical sensors, then applying machine learning models trained on clinical collaborations to estimate vitals and wellness risk indicators.
What the company does
NuraLogix built DeepAffex, a cloud-based Affective AI engine, and Anura — a consumer and enterprise app performing 30-second video scans to estimate heart rate, breathing rate, blood pressure, heart rate variability, stress, BMI, and cardiovascular disease risk. TOI technology captures subtle color changes in facial skin from blood flow using conventional cameras, then applies computational models validated through peer-reviewed research collaborations NuraLogix cites across American Heart Association publications, Scientific Reports, and other journals.
Anura Telehealth extends measurement to continuous vitals during video consultations — integrating with platforms such as Zoom and Doxy.me per product materials, addressing the gap where remote visits lacked routine vital sign capture available in physical exam rooms.
Who it serves
NuraLogix serves telemedicine vendors, insurers, mobile carriers, and wellness enterprises deploying contactless monitoring at scale. Enterprise deployments include Sanitas BluaU integration in Spain cited in company news, and partnerships extending Anura into retail health kiosks and smart mirror form factors. Healthcare providers use FDA-cleared pulse rate and breathing rate measurements while additional parameters remain positioned for wellness or investigational use per regulatory footnotes on nuralogix.ai.
Buyers evaluate NuraLogix on clinical validation depth, data privacy compliance with global health regulations, and hardware agnosticism across iOS, Android, and desktop cameras.
Company background
Pozzuoli and Lee founded NuraLogix in Toronto in 2015, building on Lee’s developmental neuroscience research into facial blood flow biomarkers. The company raised over $20 million, grew to roughly 60 staff spanning neuroscientists to software engineers per award materials, and accumulated multiple U.S. patents for contactless measurement methods. Pozzuoli previously founded RuggedCom, bringing hardware industry experience to health AI commercialization.
Product and AI capabilities
TOI applies remote photoplethysmography principles enhanced by NuraLogix’s proprietary facial region detection and blood flow extraction — feeding DeepAffex models that quantify affects including mental stress and metabolic risk indicators. Anura’s contactless blood pressure claim distinguished the product in 2021 MedTech Breakthrough recognition, though U.S. regulatory status varies by parameter with FDA-cleared pulse and breathing rate versus investigational or wellness classifications for additional metrics per site disclosures.
Multilingual, multi-device deployment positions Anura for global telehealth scale — a different adoption curve than hospital PACS-integrated imaging AI from Optellum or Ultromics.
Key developments
2015: NuraLogix founded in Toronto by Pozzuoli and Lee. May 6, 2021: Anura wins MedTech Breakthrough Best Biometric Sensor Solution (nuralogix.ai, official source). 2023: Anura Telehealth launched for video consultation vitals. 2026: FDA-cleared pulse and breathing rate measurements disclosed on product pages; enterprise wellness and telehealth integrations continue.
Why it matters
NuraLogix matters because post-pandemic telehealth normalized remote consultations without solving vital sign capture — Anura Telehealth attempts to close that gap using cameras patients already own. Contactless monitoring also reaches wellness and insurance populations never enrolled in clinical device programs. Brel readers should scrutinize regulatory labels parameter-by-parameter rather than treating Anura as uniformly clinical-grade across all outputs.
Sector context
NuraLogix belongs in Brel’s AI in healthcare coverage under digital health and remote monitoring, distinct from Huma enterprise trial platforms but sharing Toronto digital health ecosystem geography with Signal 1 and PhenoTips.
Sources and references
NuraLogix MedTech Breakthrough award article (May 2021) and Anura product page.
- NuraLogix — MedTech Breakthrough Award (nuralogix.ai, May 6, 2021)
- NuraLogix — Anura (nuralogix.ai)
Reviewed July 10, 2026. Marzio Pozzuoli is CEO and co-founder.